The first FDA-approved test for genotyping human papillomavirus (HPV) types 16, 18 and/or 45 from patient samples testing positive for HPV.³³ HPV types differ in the levels of risk that they confer for developing severe dysplasia or cervical carcinoma. Genotyping of HPV in women with negative cytology who are HPV-positive aims to improve risk stratification and to ensure appropriate follow-up of patients. Among the 14 high-risk HPV types, HPV types 16, 18, and 45, are associated with around 80% of all invasive cervical cancers worldwide. These 3 HPV types are present in approximately 75% of all squamous cell carcinomas and up to 94% of cervical adenocarcinomas.